<DOC>
	<DOCNO>NCT02994563</DOCNO>
	<brief_summary>Prospective , single-arm , open label , Safety Performance clinical investigation .</brief_summary>
	<brief_title>Amnis Therapeutics Thrombectomy Device-First Man ( FIM ) Safety Performance Study</brief_title>
	<detailed_description>The Amnis Thrombectomy Device intend restore blood flow remove thrombus intracranial vessel patient experience ischemic stroke . Pre-CE mark clinical investigation . Population subject document untreated , acute ischemic stroke large vessel occlusion .</detailed_description>
	<mesh_term>Coal Tar</mesh_term>
	<criteria>1 . Aged1885years . 2 . Subject contraindicate fail ( physician withdraws tPA per physician discretion ) intravenous tissue plasminogen activator ( tPA ) therapy give local institution within national practice . Failed mean physician continue IV tPA thrombolysis ; still occlusion TICI &lt; /= 1 relevant inclusion criterion . 3 . Subject able treat within 8 hour stroke symptom onset minimum one deployment Amnis Thrombectomy Device . 4 . NIHSS score ≥8 . 5 . Prestroke mRS ( modify Rankin Scale ) score 0 1 . 6 . Thrombolysis cerebral infarction ( TICI ) ≤1 causative occlusion M1 M2 portion MCAs , anterior cerebral artery , vertebral artery , basilar artery , posterior cerebral artery ( P1 rP2 ) , confirm CT MR angiography accessible Amnis thrombectomy device ( i.e . accord IFU ; 25.5 mm ) . 7 . ASPECTS ≥6 base CT MRI perform within 60 min prior start endovascular procedure . 8 . Subject subject 's legal guardian regulation permit , sign Patient Informed Consent agree subject attend followup visit . 1 . Rapid neurological improvement prior time treatment suggest resolution signs/symptoms stroke . 2 . Estimated time symptom onset . 3 . Baseline NIHSS score &lt; 8 . 4 . BaselineNIHSS score ≥30 state coma . 5 . Baseline prestroke mRS score &gt; 1 . 6 . Baseline Thrombolysis cerebral infarction ( TICI ) &gt; 2a . 7 . Known serious sensitivity radiographic contrast agent . 8 . Arterial tortuosity , preexist stent and/o rother arterial disease would prevent device reach target vessel . 9 . Evidence moderate/large core define extensive early ischemic change Alberta Stroke Program Early CT score ( ASPECTS ) &lt; 6 . Comorbid condition : 10 . Elevated blood pressure ( systolic &gt; 185 mm Hg diastolic &gt; 110 mm Hg ) 11 . Use warfarin anticoagulation INR &gt; 3.0 . 12 . Platelet count &lt; 30,000/mm³ . 13 . Blood glucose concentration &lt; 50 mg/dL ( 2.7 mmol/L ) . 14 . CT/MRI image demonstrate smultilobar infarction ( hypodensity &gt; 1/3 cerebral hemisphere ) . 15 . CT MRI evidence mass effect , sign hemorrhage , arteriovenous malformation aneurysm intracranial tumor ( except small meningioma ) . 16 . Angiographic evidence carotid dissection , complete cervical carotid occlusion vasculitis . 17 . Clinical Symptoms CT/MRI image suggest subarachnoid hemorrhage . 18 . Imaging evidence suggests , opinion investigator , subject appropriate mechanical thrombectomy intervention ( e.g . inability navigate target lesion , moderate/large infarct poor collateral circulation , etc. ) . General relate protocol device : 19 . Known sensitivity nickel , titanium metal alloy . 20 . Subject require hemodialysis peritoneal dialysis , contraindication angiogram whatever reason . 21 . Current participation another investigational drug device study . 22 . Female pregnant lactate positive pregnancy test time admission . 23 . Subject currently use recent history illicit drug ( ) abuse alcohol ( defined regular daily consumption four alcoholic drink per day ) . 24 . Subject life expectancy &lt; 90 day . 25 . Subject comorbid disease condition would confound neurological functional evaluation compromise survival ability complete followup assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>